Sendero Wealth Management LLC Sells 254 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

Sendero Wealth Management LLC decreased its position in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 1.3% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 19,563 shares of the company’s stock after selling 254 shares during the period. Sendero Wealth Management LLC’s holdings in Neurocrine Biosciences were worth $2,698,000 at the end of the most recent quarter.

Several other large investors have also recently added to or reduced their stakes in the company. Chesley Taft & Associates LLC bought a new position in Neurocrine Biosciences during the 1st quarter worth $1,034,000. Wealth Enhancement Advisory Services LLC grew its holdings in shares of Neurocrine Biosciences by 48.5% during the 1st quarter. Wealth Enhancement Advisory Services LLC now owns 4,744 shares of the company’s stock worth $654,000 after purchasing an additional 1,550 shares in the last quarter. Park Avenue Securities LLC grew its holdings in shares of Neurocrine Biosciences by 1.1% during the 1st quarter. Park Avenue Securities LLC now owns 9,570 shares of the company’s stock worth $1,320,000 after purchasing an additional 101 shares in the last quarter. Banque Cantonale Vaudoise grew its holdings in shares of Neurocrine Biosciences by 197.2% during the 1st quarter. Banque Cantonale Vaudoise now owns 1,186 shares of the company’s stock worth $164,000 after purchasing an additional 787 shares in the last quarter. Finally, Rise Advisors LLC grew its holdings in shares of Neurocrine Biosciences by 576.9% during the 1st quarter. Rise Advisors LLC now owns 352 shares of the company’s stock worth $49,000 after purchasing an additional 300 shares in the last quarter. Institutional investors own 92.59% of the company’s stock.

Insiders Place Their Bets

In other Neurocrine Biosciences news, insider Ingrid Delaet sold 273 shares of Neurocrine Biosciences stock in a transaction on Monday, May 6th. The shares were sold at an average price of $140.55, for a total transaction of $38,370.15. Following the transaction, the insider now directly owns 7,507 shares of the company’s stock, valued at approximately $1,055,108.85. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. In related news, Director Stephen A. Sherwin sold 40,000 shares of the business’s stock in a transaction dated Wednesday, May 29th. The shares were sold at an average price of $133.46, for a total value of $5,338,400.00. Following the transaction, the director now directly owns 26,504 shares of the company’s stock, valued at approximately $3,537,223.84. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, insider Ingrid Delaet sold 273 shares of the company’s stock in a transaction dated Monday, May 6th. The shares were sold at an average price of $140.55, for a total transaction of $38,370.15. Following the sale, the insider now directly owns 7,507 shares in the company, valued at $1,055,108.85. The disclosure for this sale can be found here. Insiders have sold 88,697 shares of company stock valued at $11,975,615 in the last three months. 4.30% of the stock is currently owned by insiders.

Analysts Set New Price Targets

Several research firms have recently issued reports on NBIX. UBS Group increased their target price on Neurocrine Biosciences from $174.00 to $193.00 and gave the stock a “buy” rating in a report on Tuesday, May 28th. Guggenheim increased their target price on Neurocrine Biosciences from $164.00 to $170.00 and gave the stock a “buy” rating in a report on Thursday, May 2nd. Morgan Stanley reissued an “overweight” rating and set a $160.00 target price on shares of Neurocrine Biosciences in a report on Wednesday, June 12th. Evercore ISI started coverage on Neurocrine Biosciences in a report on Tuesday, May 14th. They set an “outperform” rating and a $175.00 target price on the stock. Finally, Needham & Company LLC reaffirmed a “hold” rating on shares of Neurocrine Biosciences in a research note on Wednesday, May 1st. Six analysts have rated the stock with a hold rating, nineteen have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, Neurocrine Biosciences currently has a consensus rating of “Moderate Buy” and a consensus price target of $152.00.

Neurocrine Biosciences Stock Performance

Shares of NASDAQ NBIX traded up $3.36 during midday trading on Friday, reaching $137.67. The stock had a trading volume of 1,531,799 shares, compared to its average volume of 837,343. The firm has a market cap of $13.86 billion, a price-to-earnings ratio of 37.93 and a beta of 0.36. Neurocrine Biosciences, Inc. has a twelve month low of $93.02 and a twelve month high of $148.37. The company’s 50 day moving average price is $137.34 and its 200 day moving average price is $135.62.

Neurocrine Biosciences (NASDAQ:NBIX) last announced its quarterly earnings results on Wednesday, May 1st. The company reported $0.42 EPS for the quarter, missing analysts’ consensus estimates of $1.04 by ($0.62). The business had revenue of $515.30 million for the quarter, compared to the consensus estimate of $512.21 million. Neurocrine Biosciences had a net margin of 18.65% and a return on equity of 17.45%. Equities analysts forecast that Neurocrine Biosciences, Inc. will post 4.19 earnings per share for the current fiscal year.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.